Dr. Symon Cotton Named AI, Product Development Advisor at MedX Health

MedX Health Corp. has appointed Dr. Symon D. Cotton, accomplished medical device innovator and co-developer of SIAscopy, as a strategic advisor.

Dr. Cotton is an experienced author and leader in medical technology innovation, currently serving as head of Life Sciences at a leading technology organization. His career has been defined by work at the intersection of engineering, biology and computation, where he has successfully guided numerous companies through the development of novel medical devices and digital health platforms.

As one of the key scientific architects of Spectrophotometric Intracutaneous Analysis (SIAscopy), Dr. Cotton collaborated with Dr. Paul Matts in its early development and codification. Together, they helped establish SIAscopy as the world’s first technology to enable the simultaneous, non-invasive measurement of melanin, hemoglobin, and collagen within the skin. Their work provided the foundation for SIAscopy’s clinical adoption in dermatology and its integration into MedX’s DermSecure platform.

“Dr. Cotton’s contribution to SIAscopy was instrumental in shaping the technology that underpins MedX’s global teledermatology platform today,” MedX Health CEO John Gevisser said. “His expertise in medical device innovation and computational and AI strategy will help us to extend our leadership at the forefront of skin optics and machine learning, ensuring MedX solutions remain both clinically rigorous and commercially scalable.”

Beyond his foundational contributions, Dr. Cotton’s expertise extends to applying AI-driven analytics to medical imaging and diagnostics, a skill set directly aligned with MedX’s strategic roadmap. His leadership in computational biology, device design, and translational medicine equips MedX to further enhance its AI models trained on SIAscopy’s uniquely rich imaging datasets, driving greater diagnostic accuracy and scalability.

“I am proud to have been part of the original SIAscopy journey and excited to rejoin the field with MedX at such a pivotal moment,” Dr. Cotton stated. “With AI poised to transform teledermatology, I look forward to helping MedX leverage its unmatched imaging database and DermSecure platform to improve early skin cancer detection worldwide.”

Headquartered in Ontario, Canada, MedX Health develops non-invasive skin assessment and teledermatology. Its proprietary SIAscopy technology, integrated into the DermSecure platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in 38 territories worldwide including Canada, the United States, Australia, New Zealand, the United Kingdom, the European Union, and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure.